Liver fibrosis in overweight patients.

By V. Ratziu, P. Giral, F. Charlotte, E. Bruckert, V. Thibault, I. Theodorou, L. Khalil, G. Turpin, P. Opolon, T. Poynard. Gastroenterology, 2000

988 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/34c49daff862df16b9977297f978438e8087216f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Q. Anstee
2. S. Friedman
3. C. Day
4. S. Bellentani
5. Robert D. Goldin
6. V. Ratziu
7. H. Cortez‐Pinto
8. J. Clark

In Hepatology

1. Q. Anstee
2. S. Friedman
3. Robert D. Goldin
4. J. Clark
5. C. Day
6. A. Diehl
7. S. Bellentani
8. Y. Saiman

In Pathology and Forensic Medicine

1. J. Clark
2. C. Day
3. Robert D. Goldin
4. S. Friedman
5. S. Bellentani
6. Q. Anstee

Citations in the corpus

• Mouse models in non‐alcoholic fatty liver disease and steatohepatitis research (2006, background): “(2006), 87, 1–16 2006 Blackwell Publishing Ltd 1 (Ludwig et al. 1980; Powell et al. 1990; Wanless & Lentz 1990; Ratziu et al. 2000), dyslipidaemia (Powell et al. 1990; Sanyal 2002), insulin resistance (IR) (Powell et al. 1990; Marchesini et al. 1999; Sanyal 2002) and type II (non-insulin dependent)…”
• Histopathology of pediatric nonalcoholic fatty liver disease (2005, background): “Most subjects had mildly abnormal serum aminotransferase activity, although values ranged from normal to markedly elevated; median and ranges were alanine aminotransferase (ALT) 79 (16-664), aspartate aminotransferase 53 (22-273), and -glutamyltransferase 47 (9194).”
• The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD (2007, neutral): “5 19 (14-25) 98 (97-100) 64 (53-75) 97 (95-98) 10 33 (26-39) 97 (95-99) 78 (68-87) 94 (91-96) 15 42 (35-49) 96 (93-98) 84 (76-93) 91 (88-94) 20 49 (42-56) 94 (91-97) 88 (80-95) 88 (85-91) 25 55 (47-62) 93 (90-96) 90 (83-97) 86 (82-89) 30 59 (52-66) 92 (88-95) 91 (85-98) 83 (80-87) 35 63 (56-70) 90 (”
• The prevalence and etiology of elevated aminotransferase levels in the United States (2003, background): “First, in biopsy studies of patients referred for aminotransferase elevations, NAFLD was the most common histological finding (3, 22–24).”
• Increased Infiltration of Macrophages in Omental Adipose Tissue Is Associated With Marked Hepatic Lesions in Morbid Human Obesity (2006, background): “55 Hypertension 130/85 mmHg 2 (29) 6 (35) 8 (53) 0.”
• The Epidemiology of Nonalcoholic Fatty Liver Disease in Adults (2006, background): “In 2000, Ratziu et al found similar relationships between septal fibrosis (F2–F4) and clinical variables among 93 patients with NAFLD detected in their clinic after referral for elevated aminotransferases.(54) They found that septal fibrosis was associated with body mass index $ 28 kg.”
• Updated Definitions of Healthy Ranges for Serum Alanine Aminotransferase Levels (2002, background): “Hepatic steatosis, which contributes substantially to the development of end-stage liver decompensation (36, 37) and accelerates the progression of fibrosis in patients with HCV infection (31), responds favorably to modifications in diet and physical exercise.”
• A position statement on NAFLD/NASH based on the EASL 2009 special conference. (2010, background): “Proprietary tests validated on larger cohorts (FibroTest [100], ELF panel [101], and FibroMeter fatty liver [102]) as well as more simple clinical scores are available [40,103,104].”